Risk of Hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: A systematic review

International Journal of Drug Policy

Volumn 22, Issue 2, 2011, Pages 102-108

  Corson, Stephen ^a   Greenhalgh, David ^a   Palmateer, Norah ^b   Weir, Amanda ^b   Hutchinson, Sharon ^a,b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b HEALTH PROTECTION SCOTLAND   (United Kingdom)

Author keywords

Hepatitis C; IDUs; Re infection

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS RNA;

FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION CONTROL; INFECTION RATE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LONGITUDINAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REINFECTION; RISK REDUCTION; SHORT SURVEY; SYSTEMATIC REVIEW; VIRAL CLEARANCE; VIREMIA; VIRUS TRANSMISSION;

ACUTE DISEASE; ADULT; DRUG USERS; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; MALE; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; YOUNG ADULT;

EID: 79953049415     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2010.10.007     Document Type: Short Survey

References (25)

1. Advisory Council on the Misuse of Drugs. (2009). The primary prevention of Hepatitis C among injecting drug users. http://drugs.homeoffice.gov.uk/publication-search/acmd/acmdhepcreport22835.pdf.
2. Aitken C.K., Lewis J., Tracy S.L., Spelman T., Bharadwaj M., Bowden D.S., et al. High incidence of Hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008, 48:1749-1752.
3. Aitken C.K., Tracy S.L., Revill P., Bharadwaj M., Bowden D.S., Winter R.J., et al. Consecutive infections and clearances of different Hepatitis C virus genotypes in an injecting drug user. Journal of Clinical Virology 2008, 41:293-296.
4. Bialek S., Terrault N. The changing epidemiology and natural history of Hepatitis C virus infection. Clinics in Liver Disease 2006, 10:697-715.
5. Dore G., Micallef J. Low incidence of HCV re-infection: Exposure, testing frequency, or protective immunity?. Hepatology 2007, 45:1330.
6. Farci P., Alter H.J., Govindarajan S., Wong D.C., Engle R., Lesniewski R.R., et al. Lack of protective immunity against reinfection with Hepatitis C virus. Science 1992, 258:135-140.
7. Garfein R.S., Doherty M.C., Monterroso E.R., Thomas D.L., Nelson K.E., Vlahov D. Prevalence and incidence of Hepatitis C virus infection among young adult injection drug users. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998, 18:S11-S19.
8. Gerlach J.T., Diepolder H.M., Zachoval R., Gruener N.H., Jung M.C., Ulsenheimer A., et al. Acute Hepatitis C: High rate of both spontaneous and treatment induced viral clearance. Gastroenterology 2003, 125:80-88.
9. Granich R.M., Gilks C.F., Dyke C., de Cock K.M., Williams B.G. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: A mathematical model. Lancet 2009, 373:48-57.
10. Grebely J., Conway B., Raffa J.D., Lai C., Krajden M., Tyndall M.W. Hepatitis C virus re-infection in injection drug users. Hepatology 2006, 45:1139-1145.
11. Hagan H., des Jarlais D. HIV and HCV infection among injecting drug users. Mount Sinai Journal of Medicine 2000, 67:423-428.
12. Halfon P., Khiri H., Gerolami V., Bourliere M., Feryn J.M., Reynier P., et al. Impact of various handling and storage conditions on quantitative detection of Hepatitis C virus RNA. Journal of Hepatology 1996, 25:307-311.
13. Hutchinson S., Bird S., Taylor A., Goldberg D. Modelling the spread of Hepatitis C virus infection among injecting drug users in Glasgow: Implications for prevention. International Journal of Drug Policy 2006, 17:211-221.
14. Hutchinson S., Taylor A., Goldberg D., Gruer L. Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990-1994: Implications for control and prevention of blood-borne viruses. Addiction 2000, 95:931-940.
15. Kaplan E.H., O'Keefe E. Let the needles do the talking! Evaluating the New Haven needle exchange. Interfaces 1993, 23:7-26.
16. Kretzschmar M., Wiessing L. Modelling the transmission of Hepatitis C in injecting drug users. Hepatitis C and injecting drug use: Impact, costs and policy options. European Monitoring Centre For Drugs and Drug Addiction 2004, 143-159.
17. Mehta S.H., Cox A., Hoovere D.R., Wang X., Mao Q., Ray S., et al. Protection against persistence of Hepatitis C. The Lancet 2002, 359:1478-1483.
18. Micallef J.M., Kaldor J.M., Dore G.J. Spontaneous viral clearance following acute Hepatitis C infection: A systematic review of longitudinal studies. Journal of Viral Hepatitis 2006, 13:34-41.
19. Micallef J.M., Macdonald V., Jauncey M., Amin J., Rawlinson W., van Beek I. High incidence of Hepatitis C virus infection within a cohort of injecting drug users. Journal of Viral Hepatitis 2007, 14:413-418.
20. Murray J., Law M., Gao Z., Kaldor J. The impact of behavioural changes on the prevalence of human immunodeficiency virus and Hepatitis C among injecting drug users. International Journal of Epidemiology 2003, 32:708-714.
21. Scottish Government. (2008). Hepatitis C action plan for Scotland, Phase II. http://www.scotland.gov.uk/Resource/Doc/222750/0059978.pdf.
22. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'hUigin C., et al. Genetic variation in IL28B and spontaneous clearance of Hepatitis C virus. Nature 2009, 461:798-801.
23. van de Laar T.J., Molenkamp R., van de Berg C., Schinkel J., Beld M., Prins M., et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. Journal of Hepatology 2009, 51:667-674.
24. Vickerman P., Hickman M., Judd A. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. International Journal of Epidemiology 2007, 36:396-405.
25. Vickerman P., Platt L., Hawkes S. Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan. Sexually Transmitted Infections 2009, 85:23-30.